• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.
By REAL MONEY
Nov 25, 2016 | 02:00 PM EST
Stocks quotes in this article: AGN, LLY, TEVA

(A longer version of this article ran at 10:30 a.m. ET on our sister site TheDeal.com, which covers the M&A industry in depth. To get great M&A coverage like this even earlier in the trading day, click here.)

By Sarah Pringle

The $125 million purchase price on a deal that Allergan (AGN) announced Monday to acquire privately held Chase Pharmaceutical Corp. could ultimately expand eight-fold to $1 billion, TheDeal has learned.

Allergan didn't disclose the value of additional potential regulatory- and sales-related milestone payments for Chase's lead candidate drug CPC-201, but Chase CEO Doug Ingram told The Deal those payments could add up to an additional $875 million.

That's good news for Chase given that Ingram said the company was only worth about $15 million a year ago.

Chase is a clinical-stage drug developer, and CPC-201 is a potential Alzheimer's disease drug. Allergan's bet on the firm comes at a time when pharmaceutical giants are struggling to find treatments for Alzheimer's disease, which affects more than 5 million people in America alone.

Just this week, Eli Lilly & Co.  (LLY) saw its shares plunge on news that its promising drug solanezumab for Alzheimer's patients with mild dementia failed to meet a late-stage clinical trial's primary endpoint.

Ingram told TheDeal that amid a "continued graveyard of failed development programs" for Alzheimer's drugs, no player looked more capable than Allergan in bringing Chase's in-development therapy to the finish line. He said that's largely why Chase opted not to run a formal auction process for the company.

For Irish-based Allergan, the deal is consistent with its "stepping stone" M&A strategy. The company has picked up several smallish early stage assets like Chase since closing the sale of its generic-drug business to Teva Pharmaceutical (TEVA) in August. Following a lengthy regulatory review process, Allergan ultimately received $33.4 billion in cash and $5.4 billion in Teva stock for that deal.

Jim Cramer and TheStreet's Chief Investment Strategist Jack Mohr bought more Allergan shares on Monday for the Action Alerts PLUS charitable portfolio. Click here for a free 14-day membership to the AAP investment club and read why, as well as to get access other exclusive content like special monthly conference calls with Cramer and Mohr.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities. Action Alerts PLUS, which Cramer and Mohr co-manages as a charitable trust, is long AGN.

TAGS: Investing | U.S. Equity | Healthcare | Markets | Mergers and Acquisitions | Stocks

More from Healthcare

An Update on My Top Small-Cap Pick and What It Means for the Overall Market

James "Rev Shark" DePorre
Sep 26, 2023 11:30 AM EDT

The good news is that the corrective action is advancing and opportunities are developing.

Moderna's Chart Messages Are Frustrating the Bulls

Bruce Kamich
Sep 19, 2023 9:20 AM EDT

The technical indicators suggest that traders should wait until a bottom pattern plays out in the shares of the vaccine maker.

This Biotech Stock Pick Is Just Starting to Make Beautiful Music

Bret Jensen
Sep 15, 2023 9:00 AM EDT

Things have started to turn up for this midcap name. Look for these shares to end the year on an up note.

UnitedHealth Shares Are Not Looking All That Healthy

Bruce Kamich
Sep 14, 2023 11:05 AM EDT

Let's take the temperature of this important Dow component.

Moderna: Is It Time to Take a Shot?

Bruce Kamich
Sep 13, 2023 12:52 PM EDT

Let's review the trends, charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:13 PM EDT BRUCE KAMICH

    8 Trading Rules from T. T. Hoyne

    You just read the header for this missive and prob...
  • 08:42 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How Elite Traders Make Big Profits
  • 02:58 PM EDT BRUCE KAMICH

    Classic Trading Rules From Bernard Baruch

    Bernard Baruch listed the rules (below) in his aut...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login